Skip to content

Micropulse Laser Photocoagulation in Diabetic Macular Edema

Micropulse Laser Photocoagulation Treatment of Diabetic Macular Edema ; 5 % Versus 15 % Duty Cycle

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07266597
Enrollment
50
Registered
2025-12-05
Start date
2025-11-30
Completion date
2027-02-01
Last updated
2025-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Macular Edema

Keywords

micropulse , diabetic macular edema

Brief summary

To assess the safety and efficacy of 532 nm subthreshold micropulse laser 5 % duty cycle compared with 15 % duty cycle in treatment of diabetic macular edema .

Detailed description

prospective interventional randomized comparative study that will be conducted on Patients with diabetic retinopathy who Are More than 18 years old with diabetic macular edema with a central retinal thickness \< 400 um and best corrected visual acuity between 6/18 and 6/60 . The participants will be divided randomly into two groups All Patients will receive single session of 532 nm subthreshold micropulse laser ,the following parameters will be used in all cases as follows,spot size : 200-µm ,exposure duration:200-ms ,power : 500-mW While duty cycle will differ between 2 groups as follows :- Group A : will be treated using 5 % duty cycle . Group B : will be treated using 15 % duty cycle . follow up visits as follows 1 week ,4 weeks 12 weeks after laser therapy .

Interventions

PROCEDUREmicropulse laser photocoagulation

micropulse laser photocoagulation in treatment of diabetic macular edema, 5% duty cycle

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patients with diabetic retinopathy who: * Are More than 18 years old . * have diabetic macular edema with a central retinal thickness \< 400 um . * have best corrected visual acuity between 6/18 and 6/60 .

Exclusion criteria

* Previous lasered retina , Anti - VEGF injection or vitrectomy . * Extensive Macular ischemia on FFA . * Media opacity . * Associated ocular pathology as glaucoma, CNV (choroidal neovascularization ) , AMD (age related macular degenerations ), epiretinal membrane vitreomacular traction and retinal vein occlusion .

Design outcomes

Primary

MeasureTime frameDescription
central macular thickness3 monthsassessment of change of central macular thickness before and after laser treatment

Contacts

Primary Contactyounis shabaan abu alhassan, resident
younis.shabaan@med.sohag.edu.eg01027389944
Backup Contactmortada ahmed abu zeid, professor
01203324446

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026